Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Department of Pathology - Division of Anatomic Pathology

CHAIR
Clifford Harding, MD, PhD, Department Chair - 216-368-3611

KEY CONTACTS
Hannah Gilmore, MD, Division Chief - 216-286-6587
Adam Baldwin, Vice President - 216-844-5678

DEPARTMENT INQUIRIES
Please call 216-844-LABS (5227)

Organ-Specific Subspecialty Diagnostic Sign-Out

Co-Leaders: Hannah Gilmore, MD and Jay Wasman, MD

  • Service consists of 12 subspecialized surgical pathology diagnostic sections, including gastrointestinal, breast, thoracic, ENT, genitourinary, gynecological, liver, cardiovascular, bone/soft tissue, neuropathology, pediatric perinatal, endocrine, and ocular
  • Expert teams of diagnostic pathologists
  • Integration of specialized immunohistochemistry and molecular tests

Specialized Service in Cytopathology

Leader: Philip Bomeisl, DO

  • Provides Rapid On-Site Evaluation at diagnostic procedures
  • Expertise in non-gyn and gynecologic cytology
  • Supports ancillary molecular testing services for diagnostic and therapeutic purposes

Specialized Service in Autopsy

Leader: Holly Harper, MD

  • Subspecialty services in adult, pediatric, perinatal and neuropathology
  • Performs autopsies on internal and external cases, including private requests
  • Expert mortality staff assists in logistics

Specialized Service in Neurodegenerative Diseases

Leader: Mark Cohen, MD

  • Expertise in Alzheimer’s disease and Prion disease
  • Expert morphological diagnoses
  • Unique Creutzfeldt-Jakob disease program based on CSF analyses
  • Genetic susceptibility testing

Immunohistochemistry

Leader: Wadad Mneimneh, MD

  • Extensive test menu, including chromogenic in situ hybridization
  • Available as stand-alone test requests or with consultations
  • First-generation immunotherapy assessment antibodies available
  • Lynch syndrome risk screening (in conjunction with BRAF and methylation of MLH1 molecular testing)